Navigation Links
Advances in Blood Cancer Therapy to be Highlighted at American Society of Hematology Conference
Date:12/5/2007

WHITE PLAINS, N.Y., Dec. 5 /PRNewswire-USNewswire/ -- Researchers funded by The Leukemia & Lymphoma Society will present exciting new directions in blood cancer research at the annual American Society of Hematology (ASH) conference this week at the Georgia World Congress Center in Atlanta. Especially noteworthy are new findings in immunotherapies, personalized medicine and targeting transcription factors.

Immunotherapies: Researchers will discuss the current status of anti- cancer vaccines for patients with B-cell lymphoma; results of early clinical trials on adoptive T-cell immunotherapies for B-cell malignancies; new understanding of how immune cells known as natural killer (NK) cells can eliminate cancer cells; and the emerging role of NK cells in stem cell transplantation.

-- Vaccines for Lymphomas: Idiotype Vaccines and Beyond, Larry Kwak, M.D.,

Ph.D., The University of Texas M.D. Anderson Cancer Center, Houston,

(Saturday, Dec. 8, 9:30 a.m.).

-- Engineering Antitumor Immunity by T-cell Adoptive Immunotherapy,

Stanley Riddell, M.D., Fred Hutchinson Cancer Research Center,

Seattle, WA, (Dec. 8, 9:30 a.m.).

-- Human Natural Killer Cell Biology, Michael Caligiuri, M.D., The Ohio

State University Comprehensive Cancer Center, Columbus, (Sunday,

Dec. 9, 7:30 a.m.).

-- The Role of Natural Killer Cells in Haploidentical Hematopoietic

Transplantation, Andrea Velardi, M.D., University of Perugia, Italy,

(Dec. 9, 7:30 a.m.).

Targeting transcription factors: Transcription factors are proteins that control gene expression. Abnormalities in transcription factor activity are among the most common causes of myeloid and lymphocytic leukemias and are good targets for new drug development.

-- Targeting RUNX1 in Leukemia, John H. Bushweller, Ph.D., University of

Virginia, Charlottesville; Targeting MLL Fusion Genes in Leukemia,

Michael Thirman, M.D., University of Chicago. (Same session: Dec. 8,

2 p.m., and Dec. 9, 7:30 a.m.).

Personalized medicine: Society-funded researchers are developing new tests to distinguish biological traits (biomarkers) in cancers to identify patients who are most likely to benefit from a particular treatment and enable doctors to personalize treatment.

-- Deoxycytidine Kinase Genotype Includes Leukemia Cell Concentration of

Cytarabine 5-Triphosphate in Pediatric AML Patients, Varsha Gandhi,

Ph.D., M.D. Anderson Cancer Center, (Monday, Dec. 10, 8 a.m.).

-- Comprehensive Biomarker and Genomic Analysis Identifies p53 Status as

Major Determinant of Response to MDM2 Inhibitors in Chronic Lymphocytic

Leukemia, Shaomeng Wang, Ph.D., University of Michigan, (Dec. 10, 7:45

a.m.).

-- IgVH Mutational Status Does Not Affect Complete Remission Rate But Is

Associated with Reduced Remission Duration in CLL Patients Treated with

Fludarabine, Cyclophosphamide and Rituximab (FCR)-based Therapy, Thomas

Kipps, M.D., Ph.D., University of California, San Diego, (Tuesday,

Dec. 11, 8 a.m.).

Prior to the start of ASH, the Society will host this year's Marshall A. Lichtman Research Symposium, Chronic Lymphocytic Leukemia as a Model of Translational Research, on Friday, Dec. 7, 7 a.m., at the Omni Hotel at CNN Center in Atlanta. The program will feature several Society-funded researchers discussing all aspects of CLL, from causes to novel treatments.

About The Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society, headquartered in White Plains, NY, with 68 chapters in the United States and Canada, is the world's largest voluntary health organization dedicated to funding blood cancer research and providing education and patient services. The Society's mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. Since its founding in 1949, the Society has invested more than $550 million in research specifically targeting leukemia, lymphoma and myeloma. Last year alone, the Society made 5.1 million contacts with patients, caregivers and healthcare professionals.

For more information about blood cancer, visit http://www.LLS.org or call the Society's Information Resource Center (IRC), a call center staffed by master's level social workers, nurses and health educators who provide information, support and resources to patients and their families and caregivers. IRC information specialists are available at (800) 955-4572.

Contact: Andrea Greif

(914)821-8958, andrea.greif@lls.org


'/>"/>
SOURCE The Leukemia & Lymphoma Society
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Ovation further advances development pipeline with new phase III epilepsy study
2. Medical, technological advances prompt updating of nuclear medicine technologists scope of practice
3. Major grant advances UWs clinical and translational research enterprise
4. Plastic Surgery 2007: Where Truth Behind Emerging Cosmetic Treatments Meets Amazing Reconstructive Advances
5. Innovation and Medical Advances to be Highlighted on Final Day of Inaugural AdvaMed 2007 Conference
6. Despite Advances in the Accuracy of CT Colonography in Detecting Polyps, Digestive Health Experts Urge Patients to Consider Risks and Realities
7. Advances in drug screening: building a better haystack for the needles of tomorrow
8. Advances in Cancer Research, Funding Stem Cell Research, and More at Annual Cancer Congress
9. UCLA, Tokyo University nanobiotechnology symposium at UCLA to highlight advances in nanomedicine
10. Springer adds Advances in Therapy to journals portfolio
11. NIH grant advances dentistry schools work on psychosocial stress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/19/2017)... ... ... The Citadel’s new Swain Department of Nursing , along with its ... Joseph was engaged by the college as a consultant to help build the curriculum ... nation-wide search, she was selected to head the department as nurse administrator, assuming the ...
(Date:2/18/2017)... ... February 17, 2017 , ... ... **FDAnews Free Webinar**, March 1, 2017 — 1:30 p.m. – 2:30 p.m. ... burden? Pay dividends in enhanced and predictable product performance? Streamline processes resulting ...
(Date:2/18/2017)... ... 18, 2017 , ... ProParagraph Fashion Volume 2 features 30 ... Fashion Volume 2 for all multi-line FCPX project needs. Great for website ... choose from hand-crafted trend-setting designs with smooth animations that will add stylistic flare ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... allow for the electronic prescribing of controlled and non-controlled substances plus the ability ... of pharmacies in the United States now accept electronic prescriptions, according to the ...
(Date:2/17/2017)... (PRWEB) , ... February 17, 2017 , ... ... organizations, has been named a finalist in the 8th Annual DecisionHealth Platinum Awards ... healthcare delivery system. Qualis Health’s work is recognized across multiple award categories, highlighting ...
Breaking Medicine News(10 mins):
(Date:2/20/2017)... Research and Markets has announced the ... to 2022" report to their offering. ... An increasing number ... rising adoption of tension free repair procedures and increasing demand ... repair devices global market. However, Inconsistent reimbursement and the high ...
(Date:2/20/2017)... The global  cerebral spinal ... USD 1.4 billion by 2022, according to a ... evaluation of various techniques by neurosurgeons for improvement ... in this market. Moreover, shunt manufacturers are engaged ... improved shunts in order to tackle the pitfalls ...
(Date:2/19/2017)... ORLANDO, Fla. , Feb. 19, 2017 /PRNewswire/ ... its revenue cycle portfolio and thought leadership at ... be receiving a category leader award from KLAS. ... Learn panel discussion focused on how market trends ... future -  particularly a sophisticated, comprehensive Patient Access ...
Breaking Medicine Technology: